Bio Green Med Solution, Inc. (BGMS): Nasdaq/NYSE listing notice — Cyclacel receives Nasdaq non-compliance notice for stockholders' equity below $2.5M

Bio Green Med Solution, Inc.

Stockholders' equity $607K as of Dec 31, 2023, below Nasdaq minimum $2.5M.
Must submit compliance plan by May 10, 2024; extension up to 180 days possible.
No immediate delisting, but failure to regain compliance could lead to delisting of CYCC common stock.
Management reviewing options to address noncompliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 27, 2024, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company reported stockholders’ equity of less than $2.5 million as of December 31, 2023. The Company’s stockholders’ equity was $607,000 as of December 31, 2023. The Company must submit a plan to the Staff no later than May 10, 2024 advising of actions it has taken or will take to regain compliance with Nasdaq Listing

View on SEC.gov

99 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-040626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.